The crying game: Lipid-based ophthalmic nanomedicines, and in vitro models to test their performance against dry eye disease

Autores
Higa, Leticia Herminia; González Epelboim, Victoria Rebeca Dana; Ghosal, Kajal; Perez, Ana Paula; Altube, María Julia; Morilla, María José; Romero, Eder Lilia
Año de publicación
2025
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Dry eye disease (DED), the most prevalent ocular surface disorder worldwide, is currently treated with topical formulations for hydration, lubrication, or anti-inflammatory action. Due to natural barriers of the ocular surface, which limit retention and penetration of exogenous materials, the local bioavailability of topical formulations is minimal. Lipid-based nanomedicines are the most accepted nanomedicines by the pharmaceutical industry and regulatory agencies. Evaporative DED cases could benefit from topical mucoadhesive or mucopenetrating lipid-based ophthalmic nanomedicines (LBON). Besides lubricating and restoring the lipid film, topical nanomedicines offer site-specific drug delivery, magnified targeted intracellular delivery, and reduced systemic drug distribution. The resultant reduced dosing frequency may improve patients' adherence to chronic treatments. To treat DED, however, LBON must not interfere with vision or irritate, and their chemical composition, osmolarity, viscosity, pH, and refractive index must be properly selected /adjusted. Importantly, pharmacokinetics and pharmacodynamics of nanomedicines depend on the techniques used to produce each nanoparticulate structure. Hence, the structural features and resultant activities of nanomedicines prepared at lab scale, differ from those being manufactured at larger industrial scales. Due to ethical and economic reasons, preclinical assessment of LBON should therefore be performed using in vitro disease models. Here, the preclinical performances of LBON reported over the past 10 years, are critically examined. Overall, to become more significant and predictable, further preclinical developments of LBON need to become more technically rigorous and include the help of more sophisticated and broadly available in vitro models.
Fil: Higa, Leticia Herminia. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Diseño de Estrategias de Targeting de Drogas; Argentina
Fil: González Epelboim, Victoria Rebeca Dana. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Diseño de Estrategias de Targeting de Drogas; Argentina
Fil: Ghosal, Kajal. Jadavpur University; India
Fil: Perez, Ana Paula. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Diseño de Estrategias de Targeting de Drogas; Argentina
Fil: Altube, María Julia. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Diseño de Estrategias de Targeting de Drogas; Argentina
Fil: Morilla, María José. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Diseño de Estrategias de Targeting de Drogas; Argentina
Fil: Romero, Eder Lilia. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Diseño de Estrategias de Targeting de Drogas; Argentina
Materia
LIPID BASED-NANOMEDICINES
DRY EYE DISEASE
IN VITRO MODELS
OPHTALMIC
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/271137
Acceder
id CONICETDig_c4bd9d02a9ac1352f3eed4f3481975ec
oai_identifier_str oai:ri.conicet.gov.ar:11336/271137
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling The crying game: Lipid-based ophthalmic nanomedicines, and in vitro models to test their performance against dry eye diseaseHiga, Leticia HerminiaGonzález Epelboim, Victoria Rebeca DanaGhosal, KajalPerez, Ana PaulaAltube, María JuliaMorilla, María JoséRomero, Eder LiliaLIPID BASED-NANOMEDICINESDRY EYE DISEASEIN VITRO MODELSOPHTALMIChttps://purl.org/becyt/ford/2.10https://purl.org/becyt/ford/2Dry eye disease (DED), the most prevalent ocular surface disorder worldwide, is currently treated with topical formulations for hydration, lubrication, or anti-inflammatory action. Due to natural barriers of the ocular surface, which limit retention and penetration of exogenous materials, the local bioavailability of topical formulations is minimal. Lipid-based nanomedicines are the most accepted nanomedicines by the pharmaceutical industry and regulatory agencies. Evaporative DED cases could benefit from topical mucoadhesive or mucopenetrating lipid-based ophthalmic nanomedicines (LBON). Besides lubricating and restoring the lipid film, topical nanomedicines offer site-specific drug delivery, magnified targeted intracellular delivery, and reduced systemic drug distribution. The resultant reduced dosing frequency may improve patients' adherence to chronic treatments. To treat DED, however, LBON must not interfere with vision or irritate, and their chemical composition, osmolarity, viscosity, pH, and refractive index must be properly selected /adjusted. Importantly, pharmacokinetics and pharmacodynamics of nanomedicines depend on the techniques used to produce each nanoparticulate structure. Hence, the structural features and resultant activities of nanomedicines prepared at lab scale, differ from those being manufactured at larger industrial scales. Due to ethical and economic reasons, preclinical assessment of LBON should therefore be performed using in vitro disease models. Here, the preclinical performances of LBON reported over the past 10 years, are critically examined. Overall, to become more significant and predictable, further preclinical developments of LBON need to become more technically rigorous and include the help of more sophisticated and broadly available in vitro models.Fil: Higa, Leticia Herminia. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Diseño de Estrategias de Targeting de Drogas; ArgentinaFil: González Epelboim, Victoria Rebeca Dana. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Diseño de Estrategias de Targeting de Drogas; ArgentinaFil: Ghosal, Kajal. Jadavpur University; IndiaFil: Perez, Ana Paula. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Diseño de Estrategias de Targeting de Drogas; ArgentinaFil: Altube, María Julia. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Diseño de Estrategias de Targeting de Drogas; ArgentinaFil: Morilla, María José. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Diseño de Estrategias de Targeting de Drogas; ArgentinaFil: Romero, Eder Lilia. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Diseño de Estrategias de Targeting de Drogas; ArgentinaElsevier2025-09info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/271137Higa, Leticia Herminia; González Epelboim, Victoria Rebeca Dana; Ghosal, Kajal; Perez, Ana Paula; Altube, María Julia; et al.; The crying game: Lipid-based ophthalmic nanomedicines, and in vitro models to test their performance against dry eye disease; Elsevier; Journal of Drug Delivery Science and Technology; 9-2025; 1-541773-22472588-8943CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/abs/pii/S1773224725008792info:eu-repo/semantics/altIdentifier/doi/10.1016/j.jddst.2025.107476info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-nd/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-22T11:45:42Zoai:ri.conicet.gov.ar:11336/271137instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-22 11:45:43.186CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv The crying game: Lipid-based ophthalmic nanomedicines, and in vitro models to test their performance against dry eye disease
title The crying game: Lipid-based ophthalmic nanomedicines, and in vitro models to test their performance against dry eye disease
spellingShingle The crying game: Lipid-based ophthalmic nanomedicines, and in vitro models to test their performance against dry eye disease
Higa, Leticia Herminia
LIPID BASED-NANOMEDICINES
DRY EYE DISEASE
IN VITRO MODELS
OPHTALMIC
title_short The crying game: Lipid-based ophthalmic nanomedicines, and in vitro models to test their performance against dry eye disease
title_full The crying game: Lipid-based ophthalmic nanomedicines, and in vitro models to test their performance against dry eye disease
title_fullStr The crying game: Lipid-based ophthalmic nanomedicines, and in vitro models to test their performance against dry eye disease
title_full_unstemmed The crying game: Lipid-based ophthalmic nanomedicines, and in vitro models to test their performance against dry eye disease
title_sort The crying game: Lipid-based ophthalmic nanomedicines, and in vitro models to test their performance against dry eye disease
dc.creator.none.fl_str_mv Higa, Leticia Herminia
González Epelboim, Victoria Rebeca Dana
Ghosal, Kajal
Perez, Ana Paula
Altube, María Julia
Morilla, María José
Romero, Eder Lilia
author Higa, Leticia Herminia
author_facet Higa, Leticia Herminia
González Epelboim, Victoria Rebeca Dana
Ghosal, Kajal
Perez, Ana Paula
Altube, María Julia
Morilla, María José
Romero, Eder Lilia
author_role author
author2 González Epelboim, Victoria Rebeca Dana
Ghosal, Kajal
Perez, Ana Paula
Altube, María Julia
Morilla, María José
Romero, Eder Lilia
author2_role author
author
author
author
author
author
dc.subject.none.fl_str_mv LIPID BASED-NANOMEDICINES
DRY EYE DISEASE
IN VITRO MODELS
OPHTALMIC
topic LIPID BASED-NANOMEDICINES
DRY EYE DISEASE
IN VITRO MODELS
OPHTALMIC
purl_subject.fl_str_mv https://purl.org/becyt/ford/2.10
https://purl.org/becyt/ford/2
dc.description.none.fl_txt_mv Dry eye disease (DED), the most prevalent ocular surface disorder worldwide, is currently treated with topical formulations for hydration, lubrication, or anti-inflammatory action. Due to natural barriers of the ocular surface, which limit retention and penetration of exogenous materials, the local bioavailability of topical formulations is minimal. Lipid-based nanomedicines are the most accepted nanomedicines by the pharmaceutical industry and regulatory agencies. Evaporative DED cases could benefit from topical mucoadhesive or mucopenetrating lipid-based ophthalmic nanomedicines (LBON). Besides lubricating and restoring the lipid film, topical nanomedicines offer site-specific drug delivery, magnified targeted intracellular delivery, and reduced systemic drug distribution. The resultant reduced dosing frequency may improve patients' adherence to chronic treatments. To treat DED, however, LBON must not interfere with vision or irritate, and their chemical composition, osmolarity, viscosity, pH, and refractive index must be properly selected /adjusted. Importantly, pharmacokinetics and pharmacodynamics of nanomedicines depend on the techniques used to produce each nanoparticulate structure. Hence, the structural features and resultant activities of nanomedicines prepared at lab scale, differ from those being manufactured at larger industrial scales. Due to ethical and economic reasons, preclinical assessment of LBON should therefore be performed using in vitro disease models. Here, the preclinical performances of LBON reported over the past 10 years, are critically examined. Overall, to become more significant and predictable, further preclinical developments of LBON need to become more technically rigorous and include the help of more sophisticated and broadly available in vitro models.
Fil: Higa, Leticia Herminia. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Diseño de Estrategias de Targeting de Drogas; Argentina
Fil: González Epelboim, Victoria Rebeca Dana. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Diseño de Estrategias de Targeting de Drogas; Argentina
Fil: Ghosal, Kajal. Jadavpur University; India
Fil: Perez, Ana Paula. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Diseño de Estrategias de Targeting de Drogas; Argentina
Fil: Altube, María Julia. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Diseño de Estrategias de Targeting de Drogas; Argentina
Fil: Morilla, María José. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Diseño de Estrategias de Targeting de Drogas; Argentina
Fil: Romero, Eder Lilia. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Diseño de Estrategias de Targeting de Drogas; Argentina
description Dry eye disease (DED), the most prevalent ocular surface disorder worldwide, is currently treated with topical formulations for hydration, lubrication, or anti-inflammatory action. Due to natural barriers of the ocular surface, which limit retention and penetration of exogenous materials, the local bioavailability of topical formulations is minimal. Lipid-based nanomedicines are the most accepted nanomedicines by the pharmaceutical industry and regulatory agencies. Evaporative DED cases could benefit from topical mucoadhesive or mucopenetrating lipid-based ophthalmic nanomedicines (LBON). Besides lubricating and restoring the lipid film, topical nanomedicines offer site-specific drug delivery, magnified targeted intracellular delivery, and reduced systemic drug distribution. The resultant reduced dosing frequency may improve patients' adherence to chronic treatments. To treat DED, however, LBON must not interfere with vision or irritate, and their chemical composition, osmolarity, viscosity, pH, and refractive index must be properly selected /adjusted. Importantly, pharmacokinetics and pharmacodynamics of nanomedicines depend on the techniques used to produce each nanoparticulate structure. Hence, the structural features and resultant activities of nanomedicines prepared at lab scale, differ from those being manufactured at larger industrial scales. Due to ethical and economic reasons, preclinical assessment of LBON should therefore be performed using in vitro disease models. Here, the preclinical performances of LBON reported over the past 10 years, are critically examined. Overall, to become more significant and predictable, further preclinical developments of LBON need to become more technically rigorous and include the help of more sophisticated and broadly available in vitro models.
publishDate 2025
dc.date.none.fl_str_mv 2025-09
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/271137
Higa, Leticia Herminia; González Epelboim, Victoria Rebeca Dana; Ghosal, Kajal; Perez, Ana Paula; Altube, María Julia; et al.; The crying game: Lipid-based ophthalmic nanomedicines, and in vitro models to test their performance against dry eye disease; Elsevier; Journal of Drug Delivery Science and Technology; 9-2025; 1-54
1773-2247
2588-8943
CONICET Digital
CONICET
url http://hdl.handle.net/11336/271137
identifier_str_mv Higa, Leticia Herminia; González Epelboim, Victoria Rebeca Dana; Ghosal, Kajal; Perez, Ana Paula; Altube, María Julia; et al.; The crying game: Lipid-based ophthalmic nanomedicines, and in vitro models to test their performance against dry eye disease; Elsevier; Journal of Drug Delivery Science and Technology; 9-2025; 1-54
1773-2247
2588-8943
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/abs/pii/S1773224725008792
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.jddst.2025.107476
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1846782155288477696
score 12.982451

Publicaciones similares